Ocular Therapeutix sees cash runway into 2028

Total cash and cash equivalents were $391.1 million as of June 30, 2025. Based on current plans and related estimates of anticipated cash inflows from DEXTENZA, the Company believes that its current cash balance is sufficient to support its planned expenses, debt service obligations, and capital expenditure requirements into 2028. This cash projection does not yet factor in the full impact of potential clinical trial activities for AXPAXLI in NPDR and DME or the long-term extension study in wet AMD, as Ocular is currently in the planning phases for these programs.